Potent KCa3.1 channel blocker (IC50 values are 9, 14 and 15 nM for rat, human and mouse erythrocyte KCa3.1 channels respectively). Exhibits ~ 50% inhibition of KCa1.1, KV1.3, and KV11.1 channels, noradrenaline and dopamine transporters, L-type Ca2+ channels and melatonin receptors at a concentration of 10 μM. Potently inhibits IL-2 and IFN-γ production in rat lymphocytes (IC50 ~ 50 nM); reduces DBNS-induced experimental colitis in rats.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 323.33. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.09 mL||15.46 mL||30.93 mL|
|5 mM||0.62 mL||3.09 mL||6.19 mL|
|10 mM||0.31 mL||1.55 mL||3.09 mL|
|50 mM||0.06 mL||0.31 mL||0.62 mL|
References are publications that support the biological activity of the product.
Strøbæk et al (2013) NS6180, a new KCa3.1 channel inhibitor prevents T-cell activation and inflammation in a rat model of inflammatory bowel disease. Br.J.Pharmacol. 168 432 PMID: 22891655
If you know of a relevant reference for NS 6180, please let us know.
View Related Products by Product Action
Keywords: NS 6180, NS 6180 supplier, NS6180, KCa3.1, potassium, channels, blockers, inhibitors, inhibits, potent, inflammatory, bowel, disease, gardos, channel, KCNN4, anti-inflammatory, Ca2+-Activated, Potassium, Channels, 4864, Tocris Bioscience
1 Citation for NS 6180
Citations are publications that use Tocris products. Selected citations for NS 6180 include:
Abdulkareem et al (2016) Knockdown of the small conductance Ca(2+) -activated K(+) channels is potently cytotoxic in breast cancer cell lines. Circ Res 173 177 PMID: 26454020
Do you know of a great paper that uses NS 6180 from Tocris? Please let us know.
Reviews for NS 6180
There are currently no reviews for this product. Be the first to review NS 6180 and earn rewards!
Have you used NS 6180?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.